Quantitative gene expression deregulation in mantle-cell lymphoma: Correlation with clinical and biologic factors

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2770-2777

  Kienle, Dirk ^a   Katzenberger, Tiemo ^a   Ott, German ^a   Saupe, Doreen ^a   Benner, Axel ^a   Kohlhammer, Holger ^a   Barth, Thomas F E ^a   Höller, Sylvia ^a   Kalla, Jörg ^a   Rosenwald, Andreas ^a   Müller Hermelink, Hans Konrad ^a   Möller, Peter ^a   Lichter, Peter ^a   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; MYC PROTEIN; PROTEIN MDM2; PROTEIN P16; PROTEIN P27; PROTEIN P53; PROTEIN RB1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; APOPTOSIS; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME;

EID: 34447552591     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.7999     Document Type: Article

References (66)

1. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36:115-127, 1999
2. Swerdlow SH, Williams ME: From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
3. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
4. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
5. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
6. Räty R, Franssila K, Joensuu H, et al: Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69:11-20, 2002
7. Ott G, Kalla J, Ott MM, et al: Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89:1421-1429, 1997
8. Beà S, Ribas M, Hernandez JM, et al: Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365-4374, 1999
9. Tiemann M, Schrader C, Klapper W, et al: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 131:29-38, 2005
10. Katzenberger T, Petzoldt C, Holler S, et al: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107: 3407, 2006
11. Ott MM, Bartkova J, Bartek J, et al: Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 90:3154-3159, 1997
12. Pinyol M, Hernandez L, Cazorla M, et al: Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997
13. Dreyling MH, Bullinger L, Ott G, et al: Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57:4608-4614, 1997
14. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000
15. Quintanilla-Martinez L, Davies-Hill T, Fend F, et al: Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis. Blood 101:3181-3187, 2003
16. Letestu R, Ugo V, Valensi F, et al: Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia 18:953-961, 2004
17. Hernández L, Bea S, Pinyol M, etal: CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65: 2199-2206, 2005
18. Grønbaek K, Nedergaard T, Andersen MK, et al: Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 12:1266-1271, 1998
19. Fernandez V, Hartmann E, Ott G, et al: Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369, 2005
20. Camacho E, Hernandez L, Hernandez S, et al: ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99: 238-244, 2002
21. Schaffner C, Idler I, Stilgenbauer S, et al: Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A 97:2773-2778, 2000
22. Louie DC, Offit K, Jaslow R, et al: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86: 2892-2899, 1995
23. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
24. Hernandez L, Fest T, Cazorla M, et al: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996
25. Møller M, Nielsen B, Pedersen NT: Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 12:1010-1016, 1999
26. Khoury JD, Medeiros LJ, Rassidakis GZ, et al: Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high pro-liferative state, and p53 overexpression. J Pathol 199:90-97, 2003
27. Monni O, Oinonen R, Elonen E, et al: Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21:298-307, 1998
28. Bentz M, Plesch A, Bullinger L, et al: T(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27:285-294, 2000
29. Stilgenbauer S, Winkler D, Ott G, et al: Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 94:3262-3264, 1999
30. Kohlhammer H, Schwaenen C, Wessendorf S, et al: Genomic DNA-chip hybridization in t(11; 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104: 795-801, 2004
31. Schraders M, Pfundt R, Straatman HM, et al: Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 105:1686-1693, 2005
32. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
33. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
34. Kröber A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002
35. Kienle D, Kröber A, Katzenberger T, et al: VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: Correlation with genomic aberrations, clinical characteristics, and outcome. Blood 102:3003-3009, 2003
36. Korz C, Pscherer A, Benner A, et al: Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99:4554-4561, 2002
37. Kienle D, Korz C, Hosch B, et al: Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantita-tive expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 23:3780-3792, 2005
38. Bijwaard KE, Aguilera NS, Monczak Y, et al: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: Utility in the diagnosis of mantle cell lymphoma. Clin Chem 47:195-201, 2001
39. Pollard KS, van der Laan MJ: Resampling-based Multiple Testing: Asymptotic Control of Type I Error and Applications to Gene Expression Data. Division of Biostatistics, University of California, Berkeley, Technical Report 121, 2003. http://www.bepress.com/ucbbiostat/paper121
40. Bar-Joseph Z, Demaine ED, Gifford DK, et al: Fast optimal leaf ordering for hierarchical clustering. Bioinformatics 17: 22-29, 2001 (suppl 1)
41. Wand MP, Jones MC: Kernel Smoothing. London, United Kingdom, Chapman and Hall, 1995
42. Goeman JJ, van de Geer SA, de Kort F, et al: A global test for groups of genes: Testing association with a clinical outcome, Bioinformatics 20:93-99, 2004
43. Goeman JJ, Oosting J, Cleton-Jansen A, et al: Testing association of a pathway with survival using gene expression data. Bioinformatics 21:1950-1957, 2005
44. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
45. Harrell FE: Hmisc S function library. http:// biostat.mc.vanderbilt.edu/ twiki/bin/view/Main/Hmisc
46. R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2005
47. Gentleman R, Carey VJ, Bates DM, et al: Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5:R80, 2004
48. Beà S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001
49. Camacho FI, Algara P, Rodriguez A, et al: Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 101:4042-4046, 2003
50. Walsh SH, Thorselius M, Johnson A, et al: Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 101:4047-4054, 2003
51. Orchard J, Garand R, Davis Z, et al: A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101: 4975-4981, 2003
52. Nodit L, Bahler DW, Jacobs SA, et al: Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 34:1030-1034, 2003
53. Rimokh R, Berger F, Bastard C, et al: Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 83:3689-3696, 1994
54. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al: A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9:1925-1929, 1994
55. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
56. Sander B, Flygare J, Porwit-Macdonald A, et al: Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int J Cancer 117:418-430, 2005
57. Culjkovic B, Topisirovic I, Skrabanek L, et al: EIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR. J Cell Biol 169:245-256, 2005
58. Itahana K, Zou Y, Itahana Y, et al: Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23:389-401, 2003
59. Raaphorst FM, van Kemenade FJ, Fieret E, et al: Cutting edge: Polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 164:1-4, 2000
60. Breuer RH, Snijders PJ, Smit EF, et al: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736-743, 2004
61. Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5:481-488, 2003
62. Greiner TC, Dasgupta C, Ho W, et al: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 103:2352-2357, 2006
63. Solenthaler M, Matutes E, Brito-Babapulle V, et al: p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica 87:1141-1150, 2002
64. de Oca Luna RM, Tabor AD, Eberspaecher H, et al: The organization and expression of the mdm2 gene. Genomics 33:352-357, 1996
65. Ceballos E, Delgado MD, Gutierrez P, et al: C-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 19:2194-2204, 2000
66. Nagy B, Lundan T, Larramendy ML, et al: Abnormal expression of apoptosis-related genes in haematological malignancies: Overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120:434-441, 2003